3-mercaptopropionic acid has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albrecht-Küpper, B; Boor, P; Celec, P; Esposito, C; Heidland, A; Hodosy, J; Klenovicsová, K; Martin, IV; Ostendorf, T; Schäfer, S; Šebeková, K; Villa, L | 1 |
| Elbjeirami, WM | 1 |
2 other study(ies) available for 3-mercaptopropionic acid and Cirrhosis
| Article | Year |
|---|---|
The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats.
Topics: 3-Mercaptopropionic Acid; Animals; Cell Proliferation; Fibrosis; Kidney Diseases; Kidney Tubules; Nephrectomy; Peroxisome Proliferator-Activated Receptors; Protective Agents; Pyrimidines; Rats; Treatment Outcome; Ureteral Obstruction | 2011 |
PPAR-α targeting in kidney fibrosis: is BAY PP1 just another renoprotector?
Topics: 3-Mercaptopropionic Acid; Animals; Fibrosis; Kidney Diseases; Peroxisome Proliferator-Activated Receptors; Pyrimidines | 2011 |